SCHEMBL5591183

SCHEMBL5591183

Cc1ccc(-c2onc(C(=O)O)c2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 3/20 0.52
IP6K3 Q96PC2 3/20 0.52
IP6K2 Q9UHH9 3/20 0.52
MEN1 O00255 2/20 0.52
NPC1 O15118 2/20 0.52
POLB P06746 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
PTPN1 P18031 2/20 0.51
ALOX5 P09917 2/20 0.49
ALOX5AP P20292 2/20 0.49
SMURF2 Q9HAU4 1/20 0.46
SMURF1 Q9HCE7 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DUSP3 P51452 6/20 0.44
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076415 0.88 PTPN1 (0.67) IP6K1IP6K3IP6K2MEN1KMT2A
SCHEMBL1686250 0.87 ALOX5 (0.53) PTPN1ALOX5ALOX5APSMURF2SMURF1
SCHEMBL18662451 0.84 PTPN1 (0.46) IP6K1IP6K3IP6K2MEN1NPC1
SCHEMBL18662494 0.84 PTPN1 (0.46) IP6K1IP6K3IP6K2MEN1NPC1
SCHEMBL18662466 0.84 ALDH1A1 (0.52) MEN1NPC1POLBKMT2APTPN1
SCHEMBL15464353 0.83 PTPN1 (0.45) IP6K1IP6K3IP6K2MEN1NPC1
SCHEMBL18662474 0.83 TRPV1 (0.52) MEN1KMT2AMAPT
SCHEMBL768622 0.81 ALOX5 (0.48) IP6K1IP6K3IP6K2MEN1NPC1
SCHEMBL5590836 0.81 IP6K1 (0.58) IP6K1IP6K3IP6K2PTPN1SMURF2
SCHEMBL18662492 0.79 TRPV1 (0.50) IP6K1IP6K3IP6K2PTPN1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007002214-A2 ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed